Journal
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
Volume 11, Issue 5, Pages 1077-1083Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.nano.2015.02.022
Keywords
Protein nanoemulsions; Folic acid; CORM-2; Specific uptake; Targeted drug delivery
Funding
- Fundacao para a Ciencia e a Tecnologia (FCT) [SFRH/BD/81479/2011, SFRH/BD/81269/2011]
- European Union Seventh Framework Programme (FP7) [NMP4-LA-2009-228827 NANOFOL]
- FEDER through POFC-COMPETE
- Portuguese funds from FCT [PEst-OE/BIA/UI4050/2014]
- Fundação para a Ciência e a Tecnologia [SFRH/BD/81269/2011, SFRH/BD/81479/2011] Funding Source: FCT
Ask authors/readers for more resources
Folic Acid (FA)-tagged protein nanoemulsions were found to be preferentially internalized on B-cell lymphoma cell line (A20 cell line), which, for the first time, is reported to express folate receptor (FR)-alpha. Carbon monoxide releasing molecule-2 (CORM-2) was incorporated in the oil phase of the initial formulation. FA-functionalized nanoemulsions loaded with CORM-2 exhibited a considerable antitumor effect and an increased survival of BALB/c mice bearing subcutaneous A20 lymphoma tumors. The developed nanoemulsions also demonstrated to be well tolerated by these immunocompetent mice. Thus, the results obtained in this study demonstrate that FA-tagged protein nanoemulsions can be successfully used in cancer therapy, with the important ability to delivery drugs intracellularly. From the Clinical Editor: In this research, the authors developed folic acid tagged nanoemulsions containing a carbon monoxide releasing protein molecule for targeted cancer cell treatment. In-vitro and in-vivo experiments showed efficacy against B-cell lymphoma cells. The same nanocarrier platform could be applied to other tumor cells expressing folate receptors on the cell surface. (C) 2015 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available